April 7, 2024Open Access
View Full PaperInfluenza Vaccine Immune Response in Patients With High-Risk Cardiovascular Disease
Key Points
Key points are not available for this paper at this time.
Abstract
High-dose trivalent compared with standard-dose quadrivalent influenza vaccine did not significantly reduce all-cause mortality or cardiopulmonary hospitalizations in patients with high-risk cardiovascular disease in the INVESTED trial. Whether humoral immune response to influenza vaccine is associated with clinical outcomes is unknown.